rheumatoid arthritis
Conditions
Interventions
experimental group:Yiqi-Huayu-Tongbi decoction combined with stable RA treatment of Western Medicine
control group:stable RA treatment of Western Medicine
Sponsors
Guangdong Provincial Hospital of Chinese Medicine
Eligibility
Sex/Gender
All
Age
20 Years to 80 Years
Inclusion criteria
Inclusion criteria: (1) Patients who meet the 2010 ELAR/ACR RA diagnostic criteria; (2) Patients with the 10-year risk of cardiovascular disease < 10.0%; (3) Patients with 20 to 80 years of age; (4) Patients with stable RA treatment regimen before enrollment and the original treatment regimen was planned to be maintained during the study period; (5) Patients who sign the informed consent form.
Exclusion criteria
Exclusion criteria: (1) Patients with uncontrolled hypertension or systolic blood pressure = 160 mmHg and/or diastolic blood pressure = 100 mmHg after being controlled by antihypertensive drugs; (2) Patients with the presence of left coronary artery main stenosis; (3) Patients with uncontrolled tachyarrhythmias high-grade or complete conduction block and causing symptoms or hemodynamic disorders; (4) Patients who are unable to accept the tolerable exercise test; (5) Patients with acute endocarditis; (6) Patients with obstructive hypertrophic cardiomyopathy; (7) Patients with symptomatic severe aortic stenosis decompensated heart failure acute pulmonary embolism deep vein thrombosis acute pericarditis or myocarditis acute aortic dissection; (8) Patients with chronic lung disease accompanied by dyspnea; (9) Patients with recent stroke or transient ischemic attack cognitive dysfunction; (10) Patients with serious clinical complications such as uncorrected infection severe anemia and electrolyte imbalance; (11) Patients with obvious abnormalities in liver and kidney function (alanine aminotransferase or aspartate aminotransferase or creatinine > 1.5 times the upper limit of the normal reference value); (12) Patients who are taking lipid-lowering drugs; (13) Patients who have participated in other clinical studies within the last one month; (14) Other conditions that the investigator considers unsuitable for participating in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Peak oxygen pulse; | — |
Secondary
| Measure | Time frame |
|---|---|
| blood lipids;Bristol Rheumatoid Arthritis Fatigue Multi-Dimensional Questionnaire,BRAF-MDQ;erythrocyte sedimentation rate;C-reactive protein;arteriosclerotic cardiovascular disease risk ratio;Disease Activity Score 28;Lung function;Cardiac ultrasound; | — |
Countries
China
Contacts
Public ContactHuang Qingchun
Guangdong Provincial Hospital of Chinese Medicine
Outcome results
None listed